- The total Congenital Adrenal Hyperplasia market in the 7MM exceeded USD 20 million in 2023 and is projected to expand at an approximate CAGR of 40% from 2020 to 2034.
CAH is a rare genetic disorder that affects the adrenal glands, causing impaired production of essential hormones such as cortisol, aldosterone, and androgens. The condition usually appears in infancy or early childhood, with clinical manifestations ranging from salt-wasting crises to ambiguous genitalia in affected females. Early diagnosis and appropriate treatment are critical to prevent life-threatening complications and support healthy growth and development.
Congenital Adrenal Hyperplasia Market Overview
The US Congenital Adrenal Hyperplasia Treatment Market report provides a detailed overview of current treatment practices, emerging therapies, and the market share of individual therapies. It includes a thorough analysis of the CAH market size in the US from 2020 to 2034, evaluating existing treatment pathways, unmet clinical needs, and potential opportunities for market growth.
Recent Development in Congenital Adrenal Hyperplasia Clinical Research
- In December 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that the FDA approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients (ages 4 and older) with classic congenital adrenal hyperplasia (CAH). CRENESSITY, a potent and selective CRF1 receptor antagonist, is the first treatment to directly reduce excess ACTH and adrenal androgen production, enabling glucocorticoid dose reduction.
Key Congenital Adrenal Hyperplasia Companies In The Market Landscape:
The key Congenital Adrenal Hyperplasia companies in the market include –
- Neurocrine Biosciences, Inc.,
- Spruce Biosciences,
- Lundbeck,
- HBM Alpha Therapeutics,
- Crinetics Pharmaceuticals,
- BridgeBio, and others.
Congenital Adrenal Hyperplasia Epidemiology Insights
In the US, classic CAH occurs in roughly 1 in 15,000 live births, while non-classic CAH, a milder form, affects about 1 in 1,000 individuals in certain populations. Enhanced newborn screening programs have improved detection rates, particularly in developed regions. Clinical severity can differ by gender, influencing individualized treatment plans.
Key Highlights:
- In the 7MM, the US reported the highest prevalence of congenital adrenal hyperplasia in 2023, with around 32,000 cases; these figures are expected to rise over the forecast period.
👉 Access detailed epidemiology and patient segmentation – Congenital Adrenal Hyperplasia Prevalence Data
Congenital Adrenal Hyperplasia Drugs and Therapies
The Congenital Adrenal Hyperplasia (CAH) treatment landscape in the United States is evolving rapidly, moving beyond traditional lifelong glucocorticoid and mineralocorticoid replacement therapies, which can cause long-term complications such as growth suppression and metabolic disorders. Among approved therapies, EFMODY (Hydrocortisone Modified-release Hard Capsules) mimics the body’s natural cortisol rhythm, providing physiologic hormone replacement for adolescents (12+) and adults. The drug was approved by the EMA in 2021 and acquired by Neurocrine Biosciences in 2022. Innovative therapies are also emerging, including Crinecerfont, an oral CRF1 receptor antagonist that reduces excess ACTH and adrenal androgen production, addressing the root hormonal imbalance. Furthermore, BBP-631, an investigational AAV gene therapy by BridgeBio, delivers a functional 21-hydroxylase gene to the adrenal glands, aiming to restore natural cortisol and aldosterone production. These advances mark a shift toward targeted, personalized approaches, improving hormone regulation, clinical outcomes, and quality of life for US CAH patients.
Congenital Adrenal Hyperplasia Marketed Drugs
- EFMODY (Hydrocortisone Modified-release Hard Capsules): Neurocrine Biosciences EFMODY mimics natural cortisol rhythms, replacing deficient cortisol in adolescents (12+) and adults with Congenital Adrenal Hyperplasia. Hydrocortisone, a glucocorticoid, helps restore hormone balance and manage symptoms. EFMODY slowly releases hydrocortisone in the intestines, following the body’s natural daily cortisol pattern. It was approved by the EMA in May 2021, launched by Diurnal in Germany, Austria, and the UK in September 2021, and acquired by Neurocrine Biosciences in November 2022 for ~USD 55 million.
Emerging Congenital Adrenal Hyperplasia Drugs
- Crinecerfont: Neurocrine Biosciences Crinecerfont is an oral, selective CRF1 receptor antagonist in development for Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency. It works by blocking the CRF1 receptor in the Hypothalamic-Pituitary-Adrenal (HPA) axis, reducing excess ACTH and adrenal androgen production. This mechanism helps restore hormone balance independently of glucocorticoids, targeting the root cause of CAH.
- BBP-631: BridgeBio BBP-631 is an investigational AAV gene therapy designed to treat CAH at its source by delivering a functional 21-hydroxylase gene to the adrenal gland. Preclinical studies show efficient and persistent gene delivery, aiming to restore natural cortisol and aldosterone production. If successful, BBP-631 could achieve hormone balance in CAH patients, offering a potential treatment beyond current therapies or clinical trials.
Congenital Adrenal Hyperplasia Market Outlook
The US CAH market is expected to grow steadily through 2034, driven by increased awareness, earlier diagnosis, and the introduction of innovative therapies. Collaborations between pharmaceutical companies and research institutions are accelerating development, while a growing patient population supports market expansion. Leading players are focusing on pipeline innovation and nationwide reach to address unmet clinical needs, particularly in pediatric populations.
Congenital Adrenal Hyperplasia Market Insights:
- In 2023, the United States accounted for the largest share of the Congenital Adrenal Hyperplasia market among the 7MM, representing roughly 60% of the total market.
👉 Discover which companies are leading the charge in Congenital Adrenal Hyperplasia drug innovation
Conclusion:
The future of Congenital Adrenal Hyperplasia management in the US is set for transformation. Emerging therapies such as Crinecerfont and BBP-631 offer the potential for better hormone control, reduced treatment complications, and improved patient quality of life. With continued research, enhanced screening programs, and novel therapeutics, the US CAH market is expected to expand significantly through 2034.
About DelveInsight
DelveInsight is a global market research and consulting firm focused exclusively on life sciences. Through integration of epidemiology, pipeline intelligence, and market analytics, DelveInsight equips pharmaceutical, biotech, and investment stakeholders with actionable insights to navigate and capitalize on complex healthcare markets.
What is the future outlook for the Congenital Adrenal Hyperplasia market in the US?
The future outlook for the US Congenital Adrenal Hyperplasia market is highly promising, supported by strong pipeline activity, increasing adoption of targeted therapies, and advances in genetic and hormonal research. Novel drugs and gene therapies are expected to reduce long-term disease burden, improve treatment adherence, and drive sustained market growth through 2034.
